Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.
New at Polyplus-transfection
AppointmentsFrench Polyplus-transfection SA named Mario Philips as new CEO. He succeeds Karsten Wilking, now a Strategic Advisor of the biotech company, specialist for innovative transfection solutions to support the gene and cell therapy market.
Polyphor AG bags funding for murepavadin
Latest NewsPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
Women’s health from niche to mainstream
OpinionWomen make up half of the world’s population. Finally, pharma companies and invetors are now beginning to pay more attention to female diseases.
Startup Labs at the Vienna BioCenter
Sponsored PublicationsThe Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in biotechnology by the next coming generation of bio-entrepreneurs. Key assets include close proximity to outstanding academic research and highly successful innovators as well as access to cutting-edge research infrastructure.
Searching for an effective treatment for COVID-19
Latest NewsApogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.
25 years IZB
Sponsored PublicationsCommemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups. The 360-page publication describes the development of the Innovation and Start- up Center for Biotechnology into the leading biotechnology center in Europe
Global bioeconomy in the spotlight
Latest News12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and developments.
B Medical Systems: Ultra-Low Freezer
ProductsB Medical Systems’ Ultra-Low Freezers are renowned internationally for their reliability and safety.
A pioneering real AI drug discovery technology
Latest NewsThe current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective treatments for a wide range of conditions. The improved use of data and the development of advanced AI-based technologies enable the fast and effective identification of drugs, accelerating drug discovery, repurposing and innovation.
Collaborating to accelerate vaccine manufacturing
Latest NewsDevelopment of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.